# Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

> **NCT05082701** · — · TERMINATED · sponsor: **Strata Oncology** · enrollment: 295 (actual)

## Conditions studied

- Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05082701
- **Lead sponsor:** Strata Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-03
- **Primary completion:** 2023-10-02
- **Final completion:** 2024-02-22
- **Target enrollment:** 295 (ACTUAL)
- **Why stopped:** Sentinel MRD test offers no additional or increased benefits to patients compared to current marketed alternatives
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082701, "Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05082701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*